Resource Summary Report

Generated by NIF on Aug 27, 2026

HEK293T

RRID:CVCL_0063
Type: Cell Line

Proper Citation

Abcam Cat# ab282205, RRID:CVCL_0063

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0063

Proper Citation: Abcam Cat# ab282205, RRID:CVCL_0063

Description: Cell line HEK293T is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: PMID:3031469, PMID:15900046, PMID:25182477, PMID:26694163, PMID:28196595, PMID:28601559, PMID:29468137, PMID:34800366

Comments: Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HEK293T

Synonyms: Hek293T, HEK-293T, HEK 293T, HEK-293-T, HEK 293 T, 293-T, 293 T, 293T, Human Embryonic Kidney 293T, 293tsA1609neo

Cross References: BTO:BTO_0002181, CLO:CLO_0050894, EFO:EFO_0001082, CLDB:cl7154, Abcam:ab255449, Abcam:ab255593, Abcam:ab282205, AddexBio:T0011002/445, ATCC:CRL-3216, BCRJ:0361, BioGRID_ORCS_Cell_line:267, BioSample:SAMN01821609, BioSample:SAMN03473454, BioSamples:SAMEA2168958, BioSamples:SAMEA2536418, BioSamples:SAMEA2536419, CCLV:CCLV-RIE 1018, CCRID:1101HUM-PUMC000091, CCRID:3101HUMGNHu17, CCRID:3101HUMSCSP502, CCRID:4201HUM-CCTCC00187, CCRID:5301HUM-KCB07044YJ, CCTCC:GDC0187, ChEMBL-Cells:CHEMBL3706569, ChEMBL-

Targets:CHEMBL3706568, CLS:300189, Cosmic:1326280, Cosmic:2440479, DSMZ:ACC-635, DSMZCellDive:ACC-635, ECACC:12022001, ENCODE:ENCBS276VDW, ENCODE:ENCBS319KKV, ENCODE:ENCBS323RYE, ENCODE:ENCBS582KZL, ENCODE:ENCBS634AAA, ENCODE:ENCBS986WKD, FCS-free:6-2-482-1-4-3, GEO:GSM1008573, GEO:GSM5936927, GEO:GSM5936928, GEO:GSM5936929, IBRC:C10683, ICLC:HTL04001, KCB:KCB 200744YJ, Lonza:504, MeSH:D057809, NCBI_Iran:C498, NCBI_Iran:C644, PRIDE:PXD000593, PRIDE:PXD001062, PRIDE:PXD001165, PRIDE:PXD001609, PRIDE:PXD004452, PRIDE:PXD006633, PRIDE:PXD006698, PRIDE:PXD012357, PRIDE:PXD013232, PRIDE:PXD016924, PRIDE:PXD018162, PRIDE:PXD018182, PRIDE:PXD019204, PRIDE:PXD028149, PRIDE:PXD029242, PRIDE:PXD029738, PRIDE:PXD030166, PubChem_Cell_line:CVCL_0063, RCB:RCB2202, TOKU-E:3537, Ubigene:YC-A006, Ubigene:YC-A007, Wikidata:Q27546876

ID: CVCL_0063

Vendor: Abcam

Catalog Number: ab282205

Hierarchy: cvcl_0045

Record Creation Time: 20250130T071618+0000

Record Last Update: 20260816T001331+0000

Ratings and Alerts

No rating or validation information has been found for HEK293T.

No alerts have been found for HEK293T.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 70061 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Cai Z, et al. (2026) The Cullin3-Ring E3 ubiquitin ligase complex and USP14 regulate spastin-mediated microtubule severing and promotion of neurite outgrowth. Neural regeneration research, 21(4), 1641.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. Cancer immunology research, 14(2), 335.

Kobayashi H, et al. (2026) Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1. Cancer research, 86(8), 1883.

Hao X, et al. (2026) Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e21623.

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer immunology research, 14(4), 640.

Tesfamariam YM, et al. (2026) Poxvirus dsDNA genomes differentially activate AIM2 or NLRP3 inflammasomes in human primary cells. The EMBO journal, 45(5), 1728.

Schwartz I, et al. (2026) Guardian ubiquitin E3 ligases target cancer-associated APOBEC3 deaminases for degradation to promote human genome integrity. Nature communications, 17(1), 1723.

Tsui M, et al. (2026) Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways. Molecular cancer research : MCR, 24(4), 242.

Xu W, et al. (2026) Single-nucleus chromatin accessibility and gene expression co-profiling by ISSAAC-seq. Nature protocols.

Zhou Z, et al. (2026) The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model. PLoS biology, 24(1), e3003603.

Zhao Y, et al. (2026) IDH1 Reprograms Nucleotide Metabolism by Inducing Chromatin Remodeling and DHODH Transcription to Drive Chemoresistance in Nasopharyngeal Carcinoma. Cancer research, 86(8), 2004.

Fan L, et al. (2026) Molecular characterization of Ebola virus glycoprotein V75A substitution in the 2018-2020 epidemic. Cell, 189(3), 818.

Lan L, et al. (2026) A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells. Cell reports, 45(2), 116909.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. Cancer discovery, 16(4), 760.

Minneci M, et al. (2026) Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. ChemMedChem, 21(1), e202501000.

Wang Y, et al. (2026) GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses. Journal of biomedical research, 40(3), 228.

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. Cancer research, 86(6), 1372.

Das D, et al. (2026) Functional rescue and AI analysis of a human inactivating GPCR mutation using a small molecule. EMBO molecular medicine, 18(2), 725.

Hoffmann C, et al. (2026) Membrane-protein-mediated phase separation orchestrates organelle contact sites. Molecular cell, 86(1), 135.